Nov 23, 2012 by Dave Williamson and Brenton FlynnGood News for Vivus and ArenaAetna's recent insurance clinical policy bulletin update should boost sales.
Nov 23, 2012 by Dave Williamson and Brenton FlynnPfizer and Bristol-Myers' Major New Drug ApprovalThis new drug just approved in Europe is due to be the industry standard.
Nov 22, 2012 by Dave Williamson and Brenton FlynnEverything You Need to Know: Pfizer, Bristol-Myers Squibb, VIVUS, Sarepta, and St. JudeMotley Fool analyst David Williamson takes us through some major health-care jumps and tumbles.
Nov 22, 2012 by Dave Williamson and Brenton Flynn1 Biotech Wall Street Thinks Has Multibagger PotentialPiper Jaffray sees huge opportunity with Sarepta, and shares have jumped as a result.
Nov 22, 2012 by Dave Williamson and Brenton FlynnMore Bad News for St. JudeMore bad news for a company already plagued by product problems.
Nov 21, 2012 by Dave WilliamsonIs Dendreon DOA in Europe?Dendreon's drug may have lost the battle for Europe before it even began.
Nov 20, 2012 by Dave Williamson and Max MacalusoWhat You Need to Know: Ligand, AVEO, and PfizerMonday's market movers in the biotech world.
Nov 19, 2012 by Dave Williamson and Max MacalusoPfizer: Win Some, Lose SomeHits and misses in Lyrica's clinical trials.
Nov 19, 2012 by Dave Williamson and Max MacalusoFDA Approval Victory a Yawner? Will Ligand's jump today be short lived?
Nov 19, 2012 by Dave Williamson and Max Macaluso1 Biotech That Is Bouncing BackBut AVEO still has a tough road ahead.
Nov 15, 2012 by Dave Williamson and Max Macaluso3 Big Biotech Trial ResultsInsights into today's binary events
Nov 15, 2012 by Dave Williamson and Max MacalusoGilead: Biotech's Smartest CannibalSwitching patients to a new drug of your own may not be a bad thing.
Nov 9, 2012 by Dave Williamson3 Biotechs Rocking Friday's MarketA quick look at some notable health care movers.
Nov 8, 2012 by Dave WilliamsonCanada Unites Against PfizerCanada's Supreme Court unites against Pfizer's Viagra patent.
Nov 8, 2012 by Dave WilliamsonIs Sarepta the Next Biotech Success Story?Where is this breakthrough biotech headed?
Nov 7, 2012 by Dave WilliamsonSarepta Earnings: Initial Key TakeawaysQuick thoughts while listening to the conference call.
Nov 7, 2012 by Dave WilliamsonHow Obama's Victory Is Impacting InsurersWith an Obamacare repeal off the table, here's how some health stocks are faring.
Nov 7, 2012 by Dave WilliamsonHow Obama's Victory Is Impacting HospitalsRepeal of Obamacare is off the table, and several stocks have made big moves today as a result.
